Bazarbachi, Ali, Boumendil, Ariane, Finel, Herve, Mohty, Mohamad, Castagna, Luca, Blaise, Didier, Peggs, Karl S., Afanasyev, Boris, Diez-Martin, J. L., Corradini, Paolo, Michonneau, David ORCID: 0000-0003-4553-3065, Robinson, Stephen, Gutierrez Garcia, Gonzalo, Bonifazi, Francesca, Yakoub-Agha, Ibrahim, Gulbas, Zafer, Bloor, Adrian, Delage, Jeremy, Esquirol, Albert, Malladi, Ram, Scheid, Christof, El-Cheikh, Jean, Ghesquieres, Herve, Montoto, Silvia, Dreger, Peter and Sureda, Anna (2019). Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 125 (1). S. 90 - 99. HOBOKEN: WILEY. ISSN 1097-0142

Full text not available from this repository.

Abstract

Background The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation-participating centers between 2010 and 2014. Results Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV. (c) 2018 American Cancer Society.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Bazarbachi, AliUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boumendil, ArianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finel, HerveUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohty, MohamadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagna, LucaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaise, DidierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peggs, Karl S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Afanasyev, BorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diez-Martin, J. L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Corradini, PaoloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Michonneau, DavidUNSPECIFIEDorcid.org/0000-0003-4553-3065UNSPECIFIED
Robinson, StephenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gutierrez Garcia, GonzaloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bonifazi, FrancescaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yakoub-Agha, IbrahimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gulbas, ZaferUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bloor, AdrianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Delage, JeremyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Esquirol, AlbertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Malladi, RamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
El-Cheikh, JeanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ghesquieres, HerveUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Montoto, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sureda, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-140709
DOI: 10.1002/cncr.31755
Journal or Publication Title: Cancer
Volume: 125
Number: 1
Page Range: S. 90 - 99
Date: 2019
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1097-0142
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
EUROPEAN GROUP; PD-1 BLOCKADE; DISEASE; NIVOLUMAB; EFFICACY; BLOOD; IDENTIFICATION; BENDAMUSTINE; REMISSIONS; HISTOLOGYMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/14070

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item